What Did Changing Sales Rep Compensation Do For GSK?
This article was originally published in Scrip
Executive Summary
Across the pharmaceutical industry there has been a lot of talk about improving reputation and building a "patient-centric" business model. GlaxoSmithKline wanted to put its money where its mouth is and prioritize patients by changing the way it compensated it sales reps. After a "bumpy road" the new model has worked well for both customers and for business as better sales calls with doctors drives new product growth, says Victoria Williams, GSK's vice president and sales director, France.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.